why choose us

300×250 Ad Slot

Drug FDA Status

Showing 10 of 178 result(s) (Page 1 of 18)
Drug Name: Lytenava

Active Ingredient: bevacizumab-vikg

Approval Date: 2026-07-24

Description: To treat patients with neovascular (wet) age-related macular degeneration

Drug Name: Simtriyo

Active Ingredient: centanafadine

Approval Date: 2026-07-24

Description: To treat attention-deficit hyperactivity disorder

Drug Name: Jideytro

Active Ingredient: zidesamtinib

Approval Date: 2026-07-22

Description: To treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after receiving a ROS1 kinase inhibitor

Drug Name: Lipfendra

Active Ingredient: enlicitide decanoate

Approval Date: 2026-07-15

Description: To reduce low-density lipoprotein cholesterol

Drug Name: Revtorpyk

Active Ingredient: gedatolisib

Approval Date: 2026-07-14

Description: In combination with fulvestran, to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting

Drug Name: Trutakna

Active Ingredient: atacicept-vymj

Approval Date: 2026-07-07

Description: To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression

Drug Name: Lumvoa

Active Ingredient: veligrotug-vvze

Approval Date: 2026-06-26

Description: To treat thyroid eye disease

Drug Name: Utebzi

Active Ingredient: tebipenem pivoxil

Approval Date: 2026-06-17

Description: To treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options

Drug Name: Ambelvist

Active Ingredient: gadoquatrane

Approval Date: 2026-06-12

Description: To detect and visualize lesions with abnormal vascularity, in conjunction with MRI

Drug Name: Zaynich

Active Ingredient: cefepime and zidebactam

Approval Date: 2026-05-29

Description: To treat complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms

300×250 Ad Slot